| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8790700 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2027
(2 years from now) | |
| US8062667 | TRIS PHARMA INC | Modified release formulations containing drug-ion exchange resin complexes |
Mar, 2029
(4 years from now) | |
Tuzistra Xr is owned by Tris Pharma Inc.
Tuzistra Xr contains Chlorpheniramine Polistirex; Codeine Polistirex.
Tuzistra Xr has a total of 2 drug patents out of which 0 drug patents have expired.
Tuzistra Xr was authorised for market use on 30 April, 2015.
Tuzistra Xr is available in suspension, extended release;oral dosage forms.
The generics of Tuzistra Xr are possible to be released after 29 March, 2029.
Drugs and Companies using CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX ingredient
Market Authorisation Date: 30 April, 2015
Treatment: NA
Dosage: SUSPENSION, EXTENDED RELEASE;ORAL
More Information on Dosage
TUZISTRA XR family patents
